Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zheng, Xuexing ^a,i   Wong, Gary ^b,c   Zhao, Yongkun ^a   Wang, Hualei ^a   He, Shihua ^b   Bi, Yuhai ^c   Chen, Weijin ^d   Jin, Hongli ^a   Gai, Weiwei ^a   Chu, Di ^d   Cao, Zengguo ^a   Wang, Chong ^a   Fan, Quanshui ^e   Chi, Hang ^a   Gao, Yuwei ^a   Wang, Tiecheng ^a   Feng, Na ^a   Yan, Feihu ^a   Huang, Geng ^a   Zheng, Ying ^e   Li, Nan ^a   Li, Yuetao ^a   Qian, Jun ^a   Zou, Yong ^d   Kobinger, Gary ^b,f,g,h   Gao, George Fu ^c   Qiu, Xiangguo ^b,f   Yang, Songtao ^a   Xia, Xianzhu ^a   more..

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c INSTITUTE OF MICROBIOLOGY   (China)

^d Changchun Institute of Biological Products Co Ltd   (China)

^e SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f Department of Medical Microbiology ^*  (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN FRAGMENT; IMMUNOLOGIC FACTOR; VIRUS ANTIBODY;

ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; EBOLAVIRUS; GUINEA PIG; HEMORRHAGIC FEVER, EBOLA; HORSE; IMMUNOLOGY; MOUSE; POST EXPOSURE PROPHYLAXIS; PROCEDURES; SERODIAGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; HORSES; IMMUNOGLOBULIN FRAGMENTS; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; POST-EXPOSURE PROPHYLAXIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84963799796     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24179     Document Type: Article

References (36)

1. CDC.gov. Outbreaks Chronology: Ebola Virus Disease, http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html (2015). (Date of access: 06/01/2016).
2. Clark D. V, Jahrling P. B, & Lawler J. V. Clinical management of filovirus-infected patients. Viruses. 4, 1668-1686, doi: 10.3390/.v4091668 (2012).
3. Guimard Y, et al. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179 Suppl 1, S268-273, doi: 10.1086/514315 (1999).
4. Baize S, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 371, 1418-1425, doi: 10.1056/NEJMoa1404505 (2014).
5. WHO.int. Ebola Situation Report - 16 December 2015 http://apps.who.int/ebola/current-situation/ebola-situation-report-16-december-2015 (2015). (Date of access: 06/01/2016).
6. Dye J. M, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA. 109, 5034-5039, doi: 10.1073/pnas.1200409109 (2012).
7. Olinger G. G. Jr, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 109, 18030-18035, doi: 10.1073/pnas.1213709109 (2012).
8. Qiu X, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 4, 138ra181, doi: 10.1126/scitranslmed.3003876 (2012).
9. Qiu X, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 514, 47-53, doi: 10.1038/nature13777 (2014).
10. Lyon G. M, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 371, 2402-2409, doi: 10.1056/NEJMoa1409838 (2014).
11. Qiu X, et al. Two-mAb Cocktail Protects Macaques Against The Makona Variant of Ebola Virus. Sci Transl Med. 8, 329ra33 (2016).
12. CDC.gov. Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies, http://www.cdc.gov/.mmwr/pdf/rr/rr5902.pdf (2010). (Date of access: 06/01/2016).
13. CDC.gov. Tetanus, http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf (2011). (Date of access: 06/01/2016).
14. Gupta M, Mahanty S, Bray M, Ahmed R, & Rollin P. E. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol. 75, 4649-4654, doi: 10.1128/JVI.75.10.4649-4654.2001 (2001).
15. Dye J. M, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA. 109, 5034-5039, doi: 10.1073/pnas.1200409109 (2012).
16. Nakayama E, & Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol. 4, 267, doi: 10.3389/.fmicb.2013.00267 (2013).
17. Wong G, & Kobinger G. P. Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev. 28, 593-601, doi: 10.1128/CMR.00014-15 (2015).
18. Mupapa K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179 Suppl 1, S18-23, doi: 10.1086/514298 (1999).
19. Erhabor O, & Adias T. C. From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa. Transfus Clin Biol. 18, 516-526, doi: 10.1016/j.tracli.2011.06.001 (2011).
20. Mikhailov V. V, Borisevich I. V, Chernikova N. K, Potryvaeva N. V, & Krasnianskii V. P. [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever]. Vopr Virusol. 39, 82-84 (1994).
21. Bente D, Gren J, Strong J. E, & Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech. 2, 12-17, doi: 10.1242/dmm.000471 (2009).
22. Jahrling P. B, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl. 11, 135-140 (1996).
23. Bray M. Defense against filoviruses used as biological weapons. Antiviral Res. 57, 53-60 (2003).
24. Black R. E, & Gunn R. A. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 69, 567-570 (1980).
25. Wilson J. A, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 287, 1664-1666 (2000).
26. Qiu X, et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. Plos neglected tropical diseases 6, e1575, doi: 10.1371/journal.pntd.0001575 (2012).
27. Wong G, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med. 4, 158ra146, doi: 10.1126/scitranslmed.3004582 (2012).
28. Maruyama T, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 73, 6024-6030 (1999).
29. Oswald W. B, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. Plos Pathog 3, e9, doi: 06-PLPA-RA-0388R2 (2007).
30. Schlesinger J. J, Foltzer M, & Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology. 192, 132-141, doi: 10.1006/viro.1993.1015 (1993).
31. Chung K. M, et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol. 80, 1340-1351, doi: 10.1128/JVI.80.3.1340-1351.2006 (2006).
32. Jayasekera J. P, Moseman E. A, & Carroll M. C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol. 81, 3487-3494, doi: 10.1128/JVI.02128-06 (2007).
33. Mehlhop E, et al. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe. 6, 381-391, doi: 10.1016/j.chom.2009.09.003 (2009).
34. Ye L, et al. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology. 351, 260-270, doi: 10.1016/j.virol.2006.03.021 (2006).
35. Farr R. S A quantitative immunochemical measure of the primary interaction between I BSA and antibody. J Infect Dis. 103, 239-262 (1958).
36. Gao J, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol. 87, 13134-13140, doi: 10.1128/JVI.02433-13 (2013).